Flossbach Von Storch SE Raises Stock Position in BioNTech SE (NASDAQ:BNTX)

Flossbach Von Storch SE lifted its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,406,843 shares of the company's stock after purchasing an additional 47,236 shares during the quarter. BioNTech comprises 2.0% of Flossbach Von Storch SE's portfolio, making the stock its 20th biggest holding. Flossbach Von Storch SE owned about 1.84% of BioNTech worth $502,160,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Perigon Wealth Management LLC boosted its stake in BioNTech by 3.9% during the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock worth $666,000 after buying an additional 224 shares during the period. Atomi Financial Group Inc. lifted its holdings in shares of BioNTech by 6.7% in the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock worth $414,000 after acquiring an additional 229 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after purchasing an additional 300 shares during the period. Blue Trust Inc. grew its holdings in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. Finally, Planning Capital Management Corp grew its holdings in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several recent analyst reports. Wells Fargo & Company assumed coverage on BioNTech in a research report on Wednesday, December 11th. They set an "overweight" rating and a $170.00 target price for the company. JPMorgan Chase & Co. dropped their price objective on BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a report on Tuesday, November 26th. HC Wainwright reiterated a "buy" rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They set a "buy" rating and a $172.00 target price for the company. Finally, Canaccord Genuity Group upped their price target on shares of BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a report on Wednesday, November 27th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $142.72.

BioNTech Stock Up 1.8 %

NASDAQ:BNTX traded up $2.13 during trading hours on Friday, reaching $120.01. The company's stock had a trading volume of 1,362,383 shares, compared to its average volume of 746,687. The stock has a 50 day moving average price of $117.26 and a two-hundred day moving average price of $110.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $28.77 billion, a P/E ratio of -57.15 and a beta of 0.17. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.